相关实验视频

Updated: Jul 3, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

普拉斯塔格兰丁E2可以通过诱导Th17细胞分化来临床缓解干眼疾病

Jingyao Chen^1,2, Yu Gong³, Xiaoyu Sun³

¹Department of Ophthalmology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.

Chemical biology & drug design

|February 16, 2024

概括

前列腺素E2 (PGE2) 通过增加T助手17 (Th17) 细胞分化促进干眼疾病. 抑制PGE2信号传递可能为干眼提供治疗策略.

科学领域:

眼科医生眼科眼科
免疫学免疫学免疫学
炎症研究炎症研究

背景情况:

干眼病 (DE) 是一种复杂的眼表状况,其病因不明.
辅助性T细胞17 (Th17) 和前列腺素E2 (PGE2) 都与DE炎症有关.

研究的目的:

通过Th17细胞调节,研究PGE2通过Th17细胞调节影响DE炎症的机制.
探索PGE2在干眼病的发病过程中的作用.

主要方法:

建立了一个斯科波胺酸诱导的DE小鼠模型.
使用ELISA评估了液分泌,膜分解时间 (BUT) 和炎症标志物 (PGE2,IL-17,IL-6,TNF-α).
量化IL-17和RORγt (Th17转录因子) mRNA和蛋白质水平通过RT-qPCR和西式涂抹.
使用PGE2受体抑制剂 (AH6809) 来评估机械逆转.

主要成果:

在DE小鼠模型中,PGE2水平显著升高.
在DE小鼠中观察到IL-17和RORγt表达的增加.
PGE2加剧了DE症状,包括减少了眼分泌和BUT,并增加了眼IL-17和Th17细胞比例.
抑制PGE2受体可以逆转这些有害影响.

结论:

通过促进Th17细胞分化,PGE2在诱导干眼症状方面发挥着至关重要的作用.
准PGE2通路为治疗干眼疾病提供了潜在的治疗途径.

关键词:

它们的IL-17和IL-17.Th17差异化差异化方法眼睛干燥是指眼睛干燥.的前列腺素E2的前列腺素E2.

更多相关视频

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue

Published on: June 7, 2017

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Establishment of A Mouse Model of Aqueous Deficiency Dry Eye

Published on: November 1, 2024

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...